Furthermore, we demonstrated that inhibition of ADCY1 by carbamazepine can correct abnormal ERK1⁄2 and Akt signaling, protein synthesis, and the core symptoms of cognitive deficits in a mouse model of FXS. This evidence concerns the gene AKT1 and fragile X syndrome.